Geltor describes in vitro and ex vivo studies that demonstrate how a biodesigned recombinant elastin registered as sh-polypeptide-50, significantly stimulates the endogenous synthesis of key extracellular matrix components
The sharp decline in estrogen during the menopausal transition accelerates degenerative changes in the ultrastructure of elastin fibres,1 reduces collagen levels,2 and lowers concentrations of hydrophilic glucosaminoglycans in the skin.3
These changes contribute to decreased skin elasticity—up to 1.5% per year in early postmenopause—along with increased dryness, thinning, and wrinkle formation.4 Given elastin's extremely low natural turnover and the body's limited ability to regenerate it, restoring elastic fibre integrity remains a critical, yet under-addressed, target in menopausal skin care.
In this article, we describe in vitro and ex vivo studies that demonstrate Elastapure®, a biodesigned recombinant elastin registered as sh-polypeptide-50, significantly stimulates the endogenous synthesis of key extracellular matrix components.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
